Investing in biotech stocks isn't for everyone because the very nature of their business is fraught with risk. As a result, ...

This was the stock's third consecutive day of losses.

In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report). The company’s ...

South Africa's Competition Commission initiated an investigation into Vertex Pharmaceuticals for alleged excessive pricing ...

Saudi Arabia’s Ministry of Industry and Mineral Resources signed a memorandum of understanding (MoU) with US-based Vertex ...

Most sickle cell disease patients who received the gene-editing therapy Casgevy have been free from vaso-occlusive crises for ...

Editas Medicine said on Thursday it would cut around 180 jobs, representing 65% of its workforce, over the next six months as part of the company's transition towards becoming a developer of therapies ...

Though M&A deal value and volume both declined in biopharma in 2024 compared to the year prior, PwC analysts still believe ...

As reported by the South China Morning Post today, Everest Medicines (HKEX 1952.HK) is accelerating its journey to become a leading biopharmaceutical company in the Asia-Pacific region, driven by ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioLife Solutions (BLFS – Research Report) and ...

After Luigi Mangione made the difficult decision to undergo spinal surgery last year for chronic back pain, he became a ...

Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological ...